6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$300M | — | — | -$242M | $75M | $355M |
| 2024 | — | -$152M | — | — | -$136M | $51M | $93M |
| 2023 | — | -$96M | — | — | -$92M | $50M | $46M |
| 2022 | — | -$89M | — | — | -$68M | $25M | $43M |
| 2021 | — | -$33M | — | — | -$24M | $5M | $80M |
| 2020 | — | -$53M | — | — | -$35M | $0 | $54M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$121M | — | — | -$107M | $75M | $114M |
| Dec '25 | — | -$91M | — | — | -$70M | $75M | $355M |
| Sep '25 | — | -$80M | — | — | -$62M | $75M | $58M |
| Jun '25 | — | -$77M | — | — | -$55M | $74M | $49M |
| Mar '25 | — | -$52M | — | — | -$55M | $51M | $55M |
| Dec '24 | — | -$43M | — | — | -$40M | $51M | $93M |
| Sep '24 | — | -$47M | — | — | -$37M | $50M | $27M |
| Jun '24 | — | -$34M | — | — | -$25M | $50M | $25M |
| Mar '24 | — | -$28M | — | — | -$34M | $50M | $69M |
| Dec '23 | — | -$26M | — | — | -$25M | $50M | $46M |
| Sep '23 | — | -$20M | — | — | -$23M | $25M | $27M |
| Jun '23 | — | -$20M | — | — | -$18M | $25M | $34M |
| Mar '23 | — | -$30M | — | — | -$26M | $25M | $137M |
| Dec '22 | — | -$32M | — | — | -$21M | $25M | $43M |
| Sep '22 | — | -$25M | — | — | -$18M | $5M | $30M |
| Jun '22 | — | -$15M | — | — | -$19M | $5M | $50M |
| Mar '22 | — | -$17M | — | — | -$9M | $5M | $112M |
| Dec '21 | — | -$17M | — | — | -$6M | $5M | $80M |
| Sep '21 | — | -$8M | — | — | -$5M | — | $86M |
| Jun '21 | — | -$3M | — | — | -$8M | — | $92M |
See the revenue and net-income charts above for Vera Therapeutics, Inc.'s multi-year trend.
As of FY2025, Vera Therapeutics, Inc. reported $75M of total debt against $355M of cash; operating income covered interest expense -41.9×.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.